Regulatory Post-Marketing Surveillance Study for Brolucizumab

Recruiting now

Conditions studied: Neovascular Age-related Macular Degeneration

In brief

This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.

Key facts

Study ID

NCT04985487

Run by

Novartis Pharmaceuticals

People needed

3000

Starts

2021-08-18

Expected to finish

2026-06-14

Last updated by the study team

2025-01-14

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information
• Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written informed consent)

You may not qualify if…

• Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation.
• Patients participating in other investigational drug trial

Where it is running

• Novartis Investigative Site — Daegu, Dalseo Gu, South Korea (enrolling)
• Novartis Investigative Site — Goyang-si, Gyeonggi-do, South Korea (enrolling)
• Novartis Investigative Site — Guri-si, Gyeonggi-do, South Korea (enrolling)
• Novartis Investigative Site — Suwon, Gyeonggi-do, South Korea (enrolling)
• Novartis Investigative Site — Iksan Si, Jeonlabuk Do, South Korea (enrolling)
• Novartis Investigative Site — Daejeon, Korea, South Korea (enrolling)
• Novartis Investigative Site — Busan, South Korea (enrolling)
• Novartis Investigative Site — Busan, South Korea (enrolling)
• Novartis Investigative Site — Busan, South Korea (enrolling)
• Novartis Investigative Site — Daegu, South Korea (enrolling)
• Novartis Investigative Site — Daegu, South Korea (enrolling)
• Novartis Investigative Site — Gwangju, South Korea (enrolling)
• Novartis Investigative Site — Gwangju, South Korea (enrolling)
• Novartis Investigative Site — Incheon, South Korea (enrolling)
• Novartis Investigative Site — Jeju City, South Korea (enrolling)
• Novartis Investigative Site — Pusan, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)
• Novartis Investigative Site — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.